Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. In perhaps the most exciting development of the new year, STAT has launched a daily mini crossword. I completed yesterday’s in 22 seconds — let me know what time you get.
The need-to-know this morning
Alumis said envudeucitinib, its oral TYK2 inhibitor, achieved multiple skin-clearance efficacy goals in two Phase 3 clinical trials involving patients with plaque psoriasis. The company plans to submit the drug to the FDA in the second half of the year.Â
Bright Minds Biosciences announced positive seizure-reduction results from a mid-stage study of its epilepsy drug candidate BMB-101.
Arrowhead’s RNAi drugs cut fat in early studies
Arrowhead Pharmaceuticals said this morning that its gene-silencing candidates helped people with obesity lose fat. The early results may heat up the competition to develop longer-lasting weight loss treatments, but more data are needed to determine whether the drugs have a place in the existing obesity market.Continue to STAT+ to read the full story…